Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1171-1177

  Bendandi, Maurizio ^a   Gocke, Christopher D ^c   Kobrin, Carol B ^d   Benko, Floyd A ^c   Sternas, Lars A ^a   Pennington, Robin ^d   Watson, Thelma M ^a   Reynolds, Craig W ^b   Gause, Barry L ^a   Duffey, Patricia L ^e   Jaffe, Elaine S ^b   Creekmore, Stephen P ^b   Longo, Dan L ^e   Kwak, Larry W ^a  

^a Division of Clinical Sciences   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; LYMPHOMA; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VACCINATION;

ADULT; AGED; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; TRANSLOCATION, GENETIC;

EID: 0032828653     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13928     Document Type: Article

References (31)

1. Stevenson, G.T. & Stevenson, F.K. Antibody to molecularly-defined antigen confined to a tumor cell surface. Nature 254, 714-716 (1975).
2. Lynch, R.G. et al. Myeloma proteins as tumor-specific transplantation antigens. Proc. Natl. Acad. Sci. USA 69, 1540-1544 (1972).
3. Kwak, L.W. et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327, 1209-1215 (1992).
4. Hsu, F.J. et al. Tumor-specific idiotype vaccines in the treatment of patients with B-Cell lymphoma-Long term results of a clinical trial. Blood 89, 3129-3135 (1997).
5. Greenberg, P.D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
6. Shu, S., Chou T. & Rosenberg, S.A. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139, 295-304 (1987).
7. Kwak, L.W., Young, H.A., Pennington, R.W. & Weeks, S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93, 10972-10977 (1996).
8. Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90, 3539-3543 (1993).
9. Lee, M.S. et al. Detection of minimal residual disease carrying the t(14;18) by DNA sequence amplification. Science 237, 175-178 (1987).
10. Gribben, J.C. et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78, 3275-3280 (1991).
11. Cortopassi, G.A. & Arnheim, N. Using the polymerase chain reaction to estimate mutation frequencies and rates in human cells. Mutat. Res. 277, 239-249 (1992).
12. Rosenberg, S.A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 3, 321-327 (1998).
13. Correale, P. et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89, 293-300 (1997).
14. Mandruzzato, S., Brasseur, F., Andry, G., Boon, T. & van der Bruggen, P. A. CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186, 785-793 (1997).
15. Kato, K., Cantwell, M.J., Sharma, S. & Kipps, T.J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest. 101, 1133-1141 (1998).
16. Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369 (1998).
17. Brossart, P. et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer. Res. 58, 732-736 (1998).
18. Kim, H.T. et al. γδ T cell recognition of tumor 1g peptide. J. Immunol. 154, 1614-1623 (1995).
19. Hsu, F.J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
20. Kwak, L.W. et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 345, 1016-1020 (1995).
21. Osterborg, A. et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type 1, major histocompatibility complex-restricted CD8-and CD4-specific T-cell response. Blood 91, 2459-2466 (1998).
22. Raffeld, M., Neckers, L., Longo, D.L. & Cossman, J. Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by an anti-idiotype. N. Engl. J. Med. 312, 1653-1658 (1985).
23. Meeker, T. et al. Emergence of idiotype variants during treatment with anti-idiotype antibodies. N. Engl. J. Med. 312, 1658-1665 (1985).
24. Lopez-Guillermo, A. et al. The clinical significance of molecular response in indolent follicular lymphomas. Blood 91, 2955-2960 (1998).
25. Grabbe, S., Beissert, S., Schwarz, T. & Granstein, R.D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today 16, 117-120 (1995).
26. Nelson, E.L. et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 88, 580-589 (1996).
27. Fisher, R.I. et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann. Intern. Med. 98, 304-309 (1983).
28. Kobrin, C.B. & Kwak, L.W. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest. 15, 577-587 (1997).
29. Schultze, J.S. et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc. Natl. Acad. Sci. USA 92, 8200-8204 (1995).
30. Schultze, J.S., Seamon, M.J., Michalak, S., Gribben, J.G. & Nadler, L.M. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 89, 3806-3816 (1997).
31. [1]Indium-oxine. J. Immunol. Meth. 43, 319-331 (1981).